ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset
Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck cancer, including a first look at overall survival data for HPV-negative patients, as the biotech enrolls for a pivotal trial in the indication.
Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck cancer, including a first look at overall survival data for HPV-negative patients, as the biotech enrolls for a pivotal trial in the indication.
